Tab Application Banner
  • Users Online: 437
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 15  |  Issue : 2  |  Page : 100-105

End of induction treatment outcomes with a novel cyclophosphamide-based regimen for severe lupus nephritis: Single-center experience from South India


1 Department of Nephrology, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Chennai, Tamil Nadu, India
2 Institute of Nephrology, Madras Medical College, Chennai, Tamil Nadu, India
3 Pathologist, Renopath, Chennai, Tamil Nadu, India

Correspondence Address:
Dr. V Jayaprakash
Department of Nephrology, SRIHER, Porur, Chennai - 600 116, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_160_19

Rights and Permissions

Background: Cyclophosphamide is commonly used along with pulse steroids for induction immunosuppression treatment of severe forms of lupus nephritis (LN). Renal outcome data for proliferative forms of LN treated with cyclophosphamide from the southern parts of Indian subcontinent are sparse. Subjects and Methods: It was an observational study done for 2 years. All patients with severe proliferative forms of LN were included. They were treated with fixed monthly single doses of 500 mg intravenous cyclophosphamide-based induction therapy along with pulse and oral steroids, as per protocol. Renal remission rates were assessed at the end of 6 months. Adverse events during the induction therapy were documented. Results: The study included 41 patients. Of them, 37 (90.24%) patients were female and 4 (9.75%) patients were male. Nephrotic syndrome was the most common renal presentation (53.66%). The most common histological class was Class IV A (75.61%). At the end of induction therapy, complete renal remission occurred in 31.7% of cases and partial remission in 34.14% of cases. Infections were the most common adverse events that occurred in 48.4% of cases. Conclusions: Renal remission was observed in 65.85% of cases. Fixed low-dose cyclophosphamide-based induction can also be given over a 6-month period. Younger age was a significant risk factor for poor renal outcomes. Failure to achieve renal remission was a risk factor for mortality.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed381    
    Printed36    
    Emailed0    
    PDF Downloaded53    
    Comments [Add]    

Recommend this journal